Chemoinformaics analysis of 2,3-Dimethoxyxanthen-9-one
| Molecular Weight | 256.257 | nRot | 2 |
| Heavy Atom Molecular Weight | 244.161 | nRig | 17 |
| Exact Molecular Weight | 256.074 | nRing | 3 |
| Solubility: LogS | -4.445 | nHRing | 1 |
| Solubility: LogP | 2.965 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 31 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 2 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 14 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 16 |
| nHA | 4 | APOL | 36.2595 |
| nHD | 0 | BPOL | 18.1145 |
| QED | 0.661 |
| Synth | 1.814 |
| Natural Product Likeliness | 0.288 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.924 |
| Pgp-sub | 0.891 |
| HIA | 0.003 |
| CACO-2 | -4.753 |
| MDCK | 0.0000366 |
| BBB | 0.344 |
| PPB | 0.824642 |
| VDSS | 0.824 |
| FU | 0.126123 |
| CYP1A2-inh | 0.889 |
| CYP1A2-sub | 0.974 |
| CYP2c19-inh | 0.852 |
| CYP2c19-sub | 0.82 |
| CYP2c9-inh | 0.498 |
| CYP2c9-sub | 0.895 |
| CYP2d6-inh | 0.247 |
| CYP2d6-sub | 0.914 |
| CYP3a4-inh | 0.257 |
| CYP3a4-sub | 0.554 |
| CL | 4.538 |
| T12 | 0.481 |
| hERG | 0.161 |
| Ames | 0.811 |
| ROA | 0.239 |
| SkinSen | 0.778 |
| Carcinogencity | 0.677 |
| EI | 0.949 |
| Respiratory | 0.61 |
| NR-Aromatase | 0.663 |
| Antiviral | Yes |
| Prediction | 0.608796 |